samedan logo
 
 
spacer
home > pmps > summer 2019 > the future of clinical trial design
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Future of Clinical Trial Design

A growing focus on new treatments for rare diseases and the proliferation of more personalised approaches to oncological drugs have changed the clinical trials landscape drastically. Ongoing technological advancements are also driving changes in how clinical trials are managed and how the necessary drug supply is developed, manufactured, and packaged.

These trends have coincided with a growing public awareness and pressure around the cost implications of getting a new drug to market; a common estimate is £1.5 billion, but some experts place it higher. If a drug fails towards the later stages of a clinical trial, the impact on the sponsor and its suppliers is often catastrophic.

The response is that companies throughout the clinical supply chain are looking to create efficiency and reduce overall costs. Many are seeking to automate processes wherever possible – both in production and trial management – to meet the demand for improved productivity while maintaining high-quality results.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Based in Rhymney, South Wales, Dave Wilson is Head of Operations at Sharp Clinical Services. Dave began with Sharp in May 2016 and has over 18 years of end-toend fast-moving consumer goods operations management experience, including project management, planning, warehousing, despatch, and transport. Prior to joining Sharp, Dave worked as Operations Director at Amcor Flexibles and has previously worked for Unilever and Reckitt Benckiser.

Based in Bethlehem, US, John Morrison is General Manager at Sharp Clinical Services US. John is an economics graduate with over 26 years’ experience in the clinical trial packaging and logistics market. Before joining the company, he was General Manager of Clinical US Operations at Catalent Pharma Solutions, where he was responsible for significant growth in both revenue and operating profits.
spacer
Dave Wilson
spacer
spacer
spacer
John Morrison
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Avacta Announces FDA Approval of its Investigational New Drug (IND) Application for AVA6000

Cambridge and Wetherby, UK, 29 November 2021: Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms, is pleased to announce that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for AVA6000. This will allow the Group to expand its Phase 1 clinical trial, ALS-6000-101, into clinical trial sites in the United States.
More info >>

White Papers

Maximize the ROI of Your Post-Approval Research

Bioclinica

Expenditures in post-approval (Phase IV) research are going up across the pharmaceutical, biotech and medical device industries. Given the resources you’ve committed to post-approval research, you may be wondering if you’re getting the greatest possible return on your investment. Discover how to harness the power of post-approval research to increase data collection, reduce resource burn, save money, and maximize your ROI!
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement